Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB-101 + obinutuzumab
- Development stage
- Unknown
- Lead developer
- Artiva Biotherapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cell Therapies
- Administration
- Intravenous
01
Overview
AB-101 + obinutuzumab is a **combination therapy** consisting of **AB-101**, an allogeneic, non-genetically modified, cord blood-derived, cryopreserved natural killer (NK) cell product, and **obinutuzumab**, a humanized anti-CD20 monoclonal antibody. AB-101 is optimized for combination with monoclonal antibodies like obinutuzumab to enhance antibody-dependent cellular cytotoxicity (ADCC) against malignant or autoreactive B-cells. The therapy is being investigated primarily in **autoimmune diseases** such as lupus nephritis and systemic lupus erythematosus (SLE), particularly in relapsed/refractory cases that failed standard therapies. The mechanism centers on boosting the efficacy of anti-CD20-mediated B-cell depletion through enhanced NK cell-driven ADCC[1][3][6].
- Brand names
- Gazyva
- Other names
- AlloNK + obinutuzumab
02
Targets
CD20 (B-lymphocyte antigen CD20)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on AB-101 + obinutuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB-101 + obinutuzumab.